Literature DB >> 9211180

History of hypertension in patients treated for end-stage renal disease.

T V Perneger1, P K Whelton, M J Klag.   

Abstract

OBJECTIVES: To describe patterns of hypertension history in patients with various types of end-stage renal disease (ESRD) and in persons with normal kidney function; and to identify risk factors for the diagnosis 'hypertensive ESRD'.
DESIGN: A case-control study.
SETTING: Population-based. PARTICIPANTS: Patients with ESRD due to hypertension (n = 214), diabetes (n = 239), other specified causes (n = 181), unknown causes (n = 82) and control subjects drawn from the general population (n = 361). MAIN OUTCOME MEASURES: Participants' history of hypertension.
RESULTS: The prevalence of hypertension was 90% in ESRD patients and 27% in controls. Only 6% of patients with hypertensive ESRD had a history of malignant hypertension. Patients with hypertensive ESRD were more likely to have been hospitalized because of hypertension (36%) than were other ESRD patients (18%) or controls (5%). ESRD of any cause was more strongly associated with hypertension of > or = 25 years duration (odds ratio 51.0, compared with normal blood pressure) than it was with hypertension of shorter duration (15-25 years: odds ratio 31.8, 5-15 years: odds ratio 16.0, < 5 years: odds ratio 21.2). Among patients who had both hypertension and ESRD, the diagnosis of 'hypertensive ESRD' was associated independently with a long duration of hypertension, greater severity of hypertension, the absence of diabetes, black race, and limited education.
CONCLUSIONS: Hypertension is common among patients with ESRD. The risk of ESRD from any cause increases progressively with the duration of hypertension, and with indicators of severe hypertension. This result supports the hypothesis that nonmalignant hypertension of long duration may cause renal insufficiency. The criteria used to diagnose hypertensive ESRD are consistent with pathophysiologic and epidemiologic evidence.

Entities:  

Mesh:

Year:  1997        PMID: 9211180     DOI: 10.1097/00004872-199715040-00016

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 2.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

3.  Cardiovascular risk factors in CKD associate with both ESRD and mortality.

Authors:  Paul Muntner; Suzanne E Judd; Liyan Gao; Orlando M Gutiérrez; Dana V Rizk; William McClellan; Mary Cushman; David G Warnock
Journal:  J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 10.121

4.  Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study.

Authors:  Hsin-Hua Chen; Ching-Heng Lin; Kuo-Lung Lai; Tsu-Yi Hsieh; Yi-Ming Chen; Chih-Wei Tseng; Donald F Gotcher; Yu-Mei Chang; Chuang-Chun Chiou; Shih-Chia Liu; Shao-Jen Weng
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

5.  End-stage renal disease in Taiwan: a case-control study.

Authors:  Su-Ying Tsai; Hung-Fu Tseng; Hsiu-Fen Tan; Yu-Shu Chien; Chia-Chu Chang
Journal:  J Epidemiol       Date:  2009-06-20       Impact factor: 3.211

6.  Blood Pressure and Chronic Kidney Disease Stratified by Gender and the Use of Antihypertensive Drugs.

Authors:  Michihiro Satoh; Takuo Hirose; Shingo Nakayama; Takahisa Murakami; Kyosuke Takabatake; Kei Asayama; Yutaka Imai; Takayoshi Ohkubo; Takefumi Mori; Hirohito Metoki
Journal:  J Am Heart Assoc       Date:  2020-08-14       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.